Every 8-K that GE HealthCare Technologies Inc. (GEHC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GEHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GEHC filings page.
GE HealthCare Technologies Inc. (GEHC) announced that its Board of Directors has appointed Pascal Desroches to serve as a director, effective January 4, 2027. He will also join the Board’s Audit Committee and the Talent, Culture, and Compensation Committee on that date.
Desroches is Senior Executive Vice President and Chief Financial Officer of AT&T and plans to retire from AT&T on December 31, 2026. He brings more than 30 years of leadership experience in finance, governance, and large-scale technology and digital transformation, including prior roles at WarnerMedia, Turner Broadcasting, KPMG, the U.S. Securities and Exchange Commission, Honeywell Aerospace, the Federal Reserve Bank of Dallas, and DaVita. As a non-employee director, he will receive compensation under GE HealthCare’s existing non-employee director compensation program and will enter into the company’s standard indemnification agreement.
GE HealthCare Technologies Inc. appointed William (Bill) Grogan as Chief Financial Officer, effective September 14, 2026, succeeding the previously announced departure of Jay Saccaro. Interim CFO George Newcomb will cease serving in that interim role on that date and continue as Controller and Chief Accounting Officer.
Grogan joins from Xylem Inc., a global water solutions company with approximately $9 billion in revenue, where he has served as executive vice president and CFO since 2023 and helped integrate a $7.5 billion acquisition. His compensation package includes a $900,000 base salary, target annual bonus equal to 100% of base salary, annual LTI with a target grant date value of $3,300,000, a $550,000 cash sign-on payment, and a one-time sign-on RSU award with a grant date value of $4,000,000, plus an additional 2026 annual LTI award of $3,300,000.
The company describes itself as a leading global healthcare solutions provider with $20.6 billion in business and approximately 54,000 colleagues, focused on advanced medical technology, pharmaceutical diagnostics, and AI, cloud, and software solutions.
GE HealthCare Technologies Inc. reorganized its reporting structure by combining its Imaging and Advanced Visualization Solutions businesses into a new Advanced Imaging Solutions (AIS) segment and now reports three segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS), plus an Other category for HealthCare Financial Services. Exhibit 99 provides recast unaudited historical financial information under this structure, which has no impact on previously reported financial statements.
Recast data show AIS generated $14,599 million of revenue in 2025 and $3,640 million in the quarter ended March 31, 2026; total company revenue was $20,625 million in 2025 and $5,131 million in that quarter. For the March 31, 2026 quarter, segment EBIT was $479 million for AIS, $197 million for PDx, and $10 million for PCS, with income before income taxes of $505 million.
The company also presented non‑GAAP Organic revenue measures, excluding acquisitions, dispositions, and foreign currency effects. Total Organic revenue grew 3.5% year over year in 2025 and 2.9% for the quarter ended March 31, 2026, with PDx reporting the highest Organic growth rates among the segments.
GE HealthCare Technologies Inc. reported Q2 2026 revenues of $5.3 billion, up 5.7% with 3.5% organic growth. Net income attributable to GE HealthCare was $561 million, a 10.6% margin; adjusted EBIT was $750 million with a 14.2% margin. Diluted EPS was $1.24 and adjusted EPS $1.13, both benefiting from tariff refunds and a lower tax rate.
Organic orders rose 11.1%, yielding a book-to-bill of 1.15x and a $23.9 billion backlog. Advanced Imaging Solutions and Pharmaceutical Diagnostics grew strongly, while Patient Care Solutions declined and is under strategic review. Q2 free cash flow was $68 million; cash was $2.1 billion and debt $10.1 billion. The company repurchased 3.3 million shares for $200 million, declared a $0.035 dividend, and reaffirmed 2026 guidance for 3.0%–4.0% organic revenue growth, 15.4%–15.7% adjusted EBIT margin, adjusted EPS of $4.80–$5.00, and about $1.6 billion of free cash flow.
GE HealthCare Technologies Inc. reported preliminary, unaudited second quarter 2026 results. The company expects to report total revenue of $5,295 million for the three months ended June 30, 2026, up , with organic revenue of $5,182 million, reflecting 3.5% organic growth. Management also expects year-over-year growth in diluted EPS and Adjusted EPS, above its prior expectation, and reaffirmed full-year 2026 guidance.
GE HealthCare announced a leadership transition as Chief Financial Officer Jay Saccaro will resign for a role outside the medical technology industry, remaining through August 14, 2026 to support a smooth transition. George Newcomb, Controller and Chief Accounting Officer, will become interim CFO effective that date while retaining his current roles. The company emphasized that these financial results are preliminary and subject to change, with full second quarter results to be discussed on July 29, 2026.
GE HealthCare Technologies Inc. held its annual stockholder meeting on May 7, 2026, where eight directors were elected to one-year terms. Vote totals for each nominee were strong, with Peter J. Arduini receiving 363,637,737 votes for and H. Lawrence Culp, Jr. receiving 351,620,004 votes for.
Stockholders approved the advisory vote on named executive officer compensation with 351,099,781 votes for and 12,973,200 against. They also ratified Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, with 398,257,878 votes for and 769,608 against.
Effective May 7, 2026, the Board appointed Rodney F. Hochman as independent lead director and named Anne T. Madden as chairperson of the Nominating and Governance Committee, signaling updated leadership roles within the board structure.
GE HealthCare Technologies Inc. reported mixed first quarter 2026 results, combining solid revenue growth with weaker profitability and a reduced full‑year profit outlook.
Total revenues were $5.1 billion, up 7.4%, with Organic revenue growth of 2.9%, driven primarily by Pharmaceutical Diagnostics, Advanced Visualization Solutions, and Imaging across the U.S., EMEA, and Rest of World. Net income attributable to GE HealthCare fell to $389 million from $564 million, as net income margin declined to 7.6% from 11.8%. Adjusted EBIT was $691 million versus $715 million, with Adjusted EBIT margin at 13.5% compared with 15.0%. Diluted EPS was $0.85 versus $1.23, while Adjusted EPS was $0.99 versus $1.01.
Segment results were varied: Pharmaceutical Diagnostics revenue rose to $770 million with 9.7% Organic growth, but Patient Care Solutions revenue declined to $704 million with an 8.1% Organic decline and sharply lower EBIT. Management cited a discrete PDx supplier issue, higher memory chips, oil, and freight costs, and tariffs as margin headwinds, noting the PDx issue has been resolved.
Cash from operating activities was $290 million and Free cash flow was $112 million, both up year‑over‑year. The company closed the $2.3 billion Intelerad acquisition, ended the quarter with $2.3 billion of cash and cash equivalents, $10.1 billion of total debt, repurchased 1.4 million shares for $100 million, and declared a $0.035 per‑share dividend.
For full‑year 2026, GE HealthCare reaffirmed Organic revenue growth guidance of 3.0% to 4.0% but reduced profitability expectations. Adjusted EBIT margin guidance is now 15.4% to 15.7%, down from 15.8% to 16.1%. Adjusted EPS is guided to $4.80 to $5.00, versus prior guidance of $4.95 to $5.15, and Free cash flow is now expected to be approximately $1.6 billion versus prior guidance of approximately $1.7 billion. Management expects mid‑ to high‑single digit Adjusted EPS growth, assuming more pronounced inflation but partly offset by pricing and cost actions.
GE HealthCare Technologies Inc. reported that its Board appointed Kevin A. Lobo, Chair and CEO of Stryker Corporation, as a director effective March 13, 2026, and named him to the Talent, Culture, and Compensation Committee. His term runs until the 2026 Annual Meeting and he will be compensated under the company’s standard non-employee director program, with an indemnification agreement matching the form used for other directors.
The company also disclosed that directors Risa Lavizzo-Mourey and Tomislav Mihaljevic will not stand for re-election at the 2026 Annual Meeting due to other commitments, and their decisions do not reflect any disagreement with the company. A press release announcing Mr. Lobo’s appointment was issued on March 17, 2026 and furnished as an exhibit.
GE HealthCare Technologies Inc. entered into a new 364-day senior unsecured revolving credit agreement for $0.5 billion with JPMorgan Chase Bank and other lenders. This revolving credit facility matures on February 25, 2027 and can be drawn in U.S. Dollars, Euros, or Pound Sterling.
Borrowings bear interest at benchmark rates such as SOFR, EURIBOR, or SONIA, plus a margin tied to the company’s senior unsecured long-term debt ratings. The agreement includes customary covenants on liens, certain corporate transactions, leverage, and subsidiary indebtedness, along with standard events of default.
The new facility replaces a prior $0.5 billion 364-day revolving credit agreement dated March 27, 2025, which was terminated without penalty on February 26, 2026.
GE HealthCare Technologies Inc. furnished an 8-K to announce that it issued a press release with its fourth quarter 2025 and full-year 2025 financial results. The press release, dated February 4, 2026, is included as Exhibit 99 and is provided under Item 2.02, Results of Operations and Financial Condition.
The company notes that the information in Item 2.02, including Exhibit 99, is furnished rather than filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings. The 8-K also lists Exhibit 104, the cover page formatted in Inline XBRL, and is signed by the Controller and Chief Accounting Officer.
GE HealthCare Technologies Inc. arranged new debt financing to support its acquisition of Intelerad Medical Systems. The company entered into a three-year senior unsecured term loan credit facility that provides a committed $750 million term loan, to be drawn in a single borrowing on a later date once customary conditions are met and repaid in full on the third anniversary of funding. Interest can be based on either an alternate base rate or term SOFR for selected interest periods, with a margin tied to the company’s senior unsecured long-term debt ratings.
The credit agreement includes customary covenants limiting liens, certain fundamental transactions, leverage levels, and subsidiary indebtedness, along with standard events of default such as missed payments, covenant breaches, cross-acceleration of other material debt, bankruptcy events, material judgments, and change of control. Separately, GE HealthCare issued $600 million of 4.150% senior notes due December 15, 2028 and $650 million of 4.950% senior notes due December 15, 2035 under an effective shelf registration. The company plans to use the net proceeds from these notes, together with the term loan and cash on hand, to pay the purchase price of the Intelerad acquisition.
GE HealthCare Technologies Inc. (GEHC) furnished its third quarter 2025 financial results press release on an 8-K dated October 29, 2025. The press release is included as Exhibit 99.
The Item 2.02 information is furnished, not filed, and is not subject to Section 18 liabilities or incorporated by reference unless expressly stated. GE HealthCare’s common stock trades on Nasdaq under the symbol GEHC.